BML (4694) AI Stock Analysis

• Market Cap: ¥133.57B
• Dividend Yield: 2.92%
• Average Volume (3M): 60.28K
• Price to Earnings (P/E): 21.4
• Beta (1Y): 0.48
• Revenue Growth: 3.79%
• EPS Growth: 3.75%
• Country: JP
• Employees: 4,513
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 25.71
• Shares Outstanding: 42,294,426
• 10 Day Avg. Volume: 52,110
• 30 Day Avg. Volume: 60,283
• PEG Ratio: 7.23
• Price to Book (P/B): 1.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥3,825.61
• Price Target Upside: 11.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: ¥3,826.00 ▲(11.55%Upside)

The overall stock score is primarily driven by strong financial performance and robust technical indicators. Despite challenges in revenue and cash flow stability, the stock's technical momentum and fair valuation support a positive outlook.

BML Business Overview & Revenue Model

Company Description

BML (4694) is a company engaged in the manufacturing and sale of medical equipment and devices. The company operates within the healthcare sector, focusing on delivering innovative solutions that enhance patient care and streamline medical procedures. BML's core products include diagnostic imaging systems, surgical instruments, and patient monitoring devices, catering to hospitals, clinics, and other healthcare facilities globally.

How the Company Makes Money

BML (4694) generates revenue primarily through the sale of its medical equipment and devices. The company's key revenue streams include direct sales to healthcare providers, long-term supply contracts with hospitals and clinics, and partnerships with healthcare distributors. Additionally, BML might earn income from service agreements for the maintenance and repair of its equipment, ensuring long-term customer relationships and recurring revenue. The company may also engage in strategic partnerships with research institutions or other medical technology firms to enhance its product offerings and expand its market presence.

BML Financial Statement Overview

Summary

BML displays solid financial strength with strong profitability and a robust balance sheet, indicating financial stability. However, declining revenue and fluctuating free cash flow may pose future challenges.

Income Statement

BML exhibits strong profitability indicators with a consistent gross profit margin and a healthy net profit margin, reflecting effective cost management and strong revenue generation. However, the company has experienced a decline in revenue over recent years, which could be a concern for future growth. The EBIT and EBITDA margins indicate efficient operations, although they have decreased from prior years, suggesting room for improving operational efficiency.

Balance Sheet

BML maintains a robust balance sheet with a strong equity base and a low debt-to-equity ratio, indicating financial stability and a low risk of financial distress. The equity ratio suggests strong capitalization, providing a solid buffer against liabilities. The return on equity has remained healthy, showcasing efficient use of shareholders' funds despite a decrease in net income in recent periods.

Cash Flow

BML's cash flow management appears stable, with positive operating cash flow supporting its operations. However, free cash flow has fluctuated significantly, pointing to potential volatility in capital expenditures and investment activities. The operating cash flow to net income ratio demonstrates the company's ability to convert income into cash, although the volatility in free cash flow indicates potential challenges in maintaining consistent cash generation.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	143.19B	137.96B	159.46B	186.07B	138.57B
Gross Profit	45.86B	45.63B	61.45B	86.95B	54.77B
EBITDA	17.51B	16.42B	30.57B	56.26B	26.50B
Net Income	6.26B	6.03B	15.58B	33.74B	13.71B
Balance Sheet
Total Assets	177.51B	170.99B	168.94B	179.20B	139.17B
Cash, Cash Equivalents and Short-Term Investments	67.56B	74.11B	86.52B	92.13B	63.48B
Total Debt	5.29B	5.26B	4.15B	3.33B	3.25B
Total Liabilities	43.73B	40.85B	42.20B	57.52B	46.05B
Stockholders Equity	129.40B	125.86B	122.49B	116.20B	88.42B
Cash Flow
Free Cash Flow	663.00M	-6.48B	5.28B	38.52B	15.38B
Operating Cash Flow	15.81B	14.45B	11.74B	45.60B	19.57B
Investing Cash Flow	-16.79B	-21.14B	-7.63B	-7.30B	-4.58B
Financing Cash Flow	-5.43B	-5.73B	-9.71B	-9.83B	-3.38B

BML Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3430.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4694, the sentiment is Positive. The current price of 3430 is above the 20-day moving average (MA) of 3308.75, above the 50-day MA of 3153.48, and above the 200-day MA of 2883.18, indicating a bullish trend. The MACD of 66.37 indicates Negative momentum. The RSI at 74.50 is Negative, neither overbought nor oversold. The STOCH value of 75.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4694.

BML Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4694	78 Outperform	¥133.57B	21.36	4.86%	2.92%	3.79%	3.75%
4886	76 Outperform	¥63.74B	13.31		2.07%	2.06%	-32.48%
2395	71 Outperform	¥56.79B	11.53		4.40%	22.55%	-10.96%
4671	67 Neutral	¥22.97B	12.60		5.50%	0.71%	19.35%
4549	66 Neutral	¥68.28B	32.95		2.53%	1.22%	-9.27%
4544	63 Neutral	¥182.73B	65.87	1.93%	3.94%	2.56%	―
Sector *	52 Neutral	$7.36B	-0.07	-63.77%	2.36%	16.35%	0.03%

BML Corporate Events

BML, Inc. Announces Strategic Merger with Subsidiary to Enhance Efficiency

BML, Inc. has announced a strategic absorption-type merger with its wholly owned subsidiary, BML Life Science Holdings, Inc., effective September 1, 2025. This merger aims to streamline operations and improve management efficiency within the group, with BML, Inc. remaining as the surviving entity. The merger will not involve any issuance of new shares or changes to the company’s structure, ensuring a smooth transition and continued focus on core business activities.

BML, Inc. Announces Key Personnel Changes

BML, Inc. has announced a series of personnel changes following a board meeting on May 9, 2025. These changes, which involve several key positions within the company, will be finalized at the upcoming Annual General Meeting of Shareholders. The adjustments in leadership roles are expected to streamline operations and enhance the company’s strategic focus, potentially impacting its market positioning and stakeholder relations.

BML, Inc. Announces Governance Transition with New Director Appointments

BML, Inc. announced a transition to a company with an Audit and Supervisory Committee, which involves several personnel changes. The proposed candidates for director positions will be submitted for approval at the upcoming Annual General Meeting of Shareholders. This transition is expected to enhance the company’s governance structure and oversight capabilities.

BML, Inc. Proposes Amendments to Enhance Corporate Governance

BML, Inc. has announced a proposal for amendments to its Articles of Incorporation, which will be presented at the upcoming Annual General Meeting of Shareholders. The proposed changes are part of a transition to a Company with an Audit and Supervisory Committee, aimed at enhancing corporate governance by strengthening audit and supervisory functions. This transition involves integrating audit and supervisory committee members into the Board of Directors, necessitating changes in the company’s governance framework.

BML, Inc. Reports Fiscal 2024 Earnings with Increased Dividends

BML, Inc. reported its fiscal 2024 earnings, showing a modest increase in net sales and profits compared to the previous year, despite a challenging market environment. The company announced a significant increase in dividends, reflecting confidence in its financial stability and commitment to returning value to shareholders.